What is the Samson Clinical trial evaluating?

The Samson Clinical trial is evaluating the efficacy and safety of sublingual minoxidil, a new treatment for male pattern hair loss, also known as androgenetic alopecia (AGA).

When will the results of the Samson Clinical trial be released?

The initial results of the 24-week Samson Clinical trial are expected to be released in mid-2026.

What is the current status of the Samson Clinical trial?

Samson Clinical has concluded participant enrollment for its Phase III clinical trial of sublingual minoxidil, a significant milestone in the development of this new hair loss treatment.

Home / Health / Samson Clinical Completes Enrollment for Landmark Male Pattern Hair Loss Study

Samson Clinical Completes Enrollment for Landmark Male Pattern Hair Loss Study

17 Nov

•

Summary

Samson Clinical concludes participant enrollment for Phase III trial of sublingual minoxidil
Study aims to evaluate efficacy and safety of new treatment for androgenetic alopecia
Initial results expected in mid-2026

Samson Clinical Completes Enrollment for Landmark Male Pattern Hair Loss Study

Samson Clinical has reached a significant milestone in its efforts to develop a new treatment for male pattern hair loss, also known as androgenetic alopecia (AGA). The company has concluded participant enrollment for its Phase III clinical trial evaluating the efficacy and safety of sublingual (under-the-tongue) minoxidil.

The randomized, multi-center, placebo-controlled study aims to assess the effectiveness of this novel formulation of the well-known hair loss medication. Subjects were assigned in a one-to-one ratio to receive either the sublingual minoxidil or a placebo. With recruitment now complete, Samson expects to release the initial results of the 24-week trial in mid-2026.